of the 5-HT7 receptor. *Biorg. Med. Chem. Lett.* 12, 2549–2552

Daniela Barlocco
University of Milan
Viale Abruzzi 42, Milano 20131, Italy
e-mail: daniela.barlocco@unimi.it

Combinatorial chemistry

Cathepsin K inhibitors

Cathepsin K, a cysteine protease that is predominantly expressed in osteoclasts, has been implicated in bone resorption through the use of selective peptide inhibitors, antisense oligonucleotides and the existence of a human genetic disorder, pycnodysostosis. These observations provide a rationale for the use of cathepsin K inhibitors as a treatment for diseases characterized by excessive bone loss, such as osteoporosis.

Recently, the first indication that inhibition of cathepsin K leads to a reduction in bone resorption in primates was achieved. Workers at Bayer (http://www.bayer.com) performed HTS of their compound collection, which provided the micromolar hit **i** [1]. The presence of an electrophilic carbonyl group (aminomethyl ketone moiety) in this molecule suggested the possibility for reversible formation of a covalent tetrahedral adduct with the active-site Cys25 similar to the case with other reported ketone inhibitors.

A small library of 26 compounds was synthesized in solution in an attempt to elucidate SAR based on the lead compound (**i**) found from HTS screening.



(i)



(ii)

The library compounds were evaluated in a cathepsin K inhibition assay. One of the most potent compounds found was **ii**, which possessed a cathepsin K inhibition IC_{50} value of 230 nM. This work has produced a novel and useful template for cathepsin K inhibitor design and holds promise for further optimization.

1 Smith, R.A. et al. (2001) Discovery and parallel synthesis of a new class of cathepsin K inhibitors. *Bioorg. Med. Chem. Lett.* 11, 2951–2954

Liver X receptor agonists

The increased incidence of cardiovascular disease (CVD) in westernized nations has been linked to increased dietary intake of cholesterol and saturated fats and an increase in low-density lipoprotein (LDL) particles. Accumulation of small, dense LDL particles in the arterial wall leads to the formation of cholesterol-laden foam cells, which are the hallmark of coronary atherosclerosis, and activation of the immune system. Although cholesterol-lowering drugs, such as statins, reduce the incidence of CVD in patients with high circulating levels of LDL cholesterol (LDLc), atherosclerosis also afflicts individuals with relatively normal LDLc levels. In contrast to LDL, the levels of high-density lipoprotein (HDL) particles are inversely related to the incidence of CVD. The protective role of HDL might result from its role in mediating 'reverse cholesterol transport' whereby cholesterol is transported from peripheral cells back to the liver. Thus, agents that promote reverse cholesterol transport by raising circulating levels of HDL could provide an alternative therapeutic option for the prevention of atherosclerotic CVD.

The liver X receptors, LXRα (NR1H3) and LXRβ (NR1H2) are oxysterol-activated transcripted factors that belong to the nuclear hormone receptor superfamily. It has been proposed that compound **iii** is an endogenous ligand for LXRα in the liver. Upon cholesterol feeding, the hepatic levels of **iii** in rats are raised to levels consistent with its putative role as a natural LXRα agonist.



(iii)

The identification of a novel chemical series of LXR agonists through solid-phase parallel synthesis of tertiary amines has recently been reported [2]. A library of 1280 compounds was synthesised on Rink amide solid phase resin, the design of which was based on the GlaxoSmithKline (http://www.gsk.com) HTS hit **iv**. The library compounds were screened for activity in the cell-free ligand-sensing assay (LiSA) for human LXRα. The LXRα LiSA measures the ligand-dependent recruitment of a 24 amino acid fragment of the steroid receptor coactivator 1 (SRC1) to the ligand-binding domain of the receptor. One of the most potent compounds isolated was compound **v**, which possessed an EC_{50} value of 45 nM in the LXRα–SRC1 LiSA. This work has provided a novel, potent lead for the development of drugs to increase reverse cholesterol transport and further work in this area is warranted.



(iv)

(v)

2 Collins, J.L. *et al.* (2002) Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. *J. Med. Chem.* 45, 1963–1966

Paul Edwards
Discovery Chemistry
Pfizer Global Research and Development
Sandwich, Kent, UK
fax: +44 1304 643 555
e-mail: paul_edwards@sandwich.pfizer.com

 1359-6446/02/$ – see front matter PII: S1359-6446(02)02491-1